Condition: Leptomeningeal Metastasis · Leptomeningeal Disease · HER2-positive Metastatic Breast Cancer · Sponsor: UNICANCER
The goal of this clinical trial is to evaluate the efficacy of tucatinib and capecitabine in combination with intrathecal trastuzumab on overall survival rate at 12 months in HER2-positive metastatic breast cancer (MBC) patients with proven leptomeningeal evolution and requiring intrathecal therapy.
This description comes directly from the study's public registry record.
Telma ROQUE, PhD · +33 (0) 1 80 50 12 92 · t-roque@unicancer.fr
Jérôme LEMONNIER, PhD · +33 (0) 1 71 93 67 02 · j-lemonnier@unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut Bergonié | Bordeaux, France | Withdrawn |
| Centre François Baclesse | Caen, France | Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| Centre Georges-François Leclerc | Dijon, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Institut régional du Cancer de Montpellier | Montpellier, France | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Recruiting |
| Institut Jean Godinot | Reims, France | Recruiting |
| Centre Henri Becquerel | Rouen, France | Recruiting |
| Institut de cancérologie Strasbourg Europe - ICANS | Strasbourg, France | Recruiting |
| Gustave Roussy | Villejuif, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05800275